医学
内科学
心脏病学
心室
狭窄
反流(循环)
主动脉瓣
血管舒张
主动脉瓣狭窄
作者
Vasiliki Katsi,Georgios Georgiopoulos,D Oikonomou,Constadina Aggeli,Charalampos Grassos,Dimitris Papadopoulos,Costas Thomopoulos,Maria Marketou,Kyriakos Dimitriadis,Kostas Toutouzas,Jens Mogensen,Konstantinos Tsioufis,Dimitris Tousoulis
出处
期刊:Current Vascular Pharmacology
[Bentham Science]
日期:2019-01-09
卷期号:17 (2): 180-190
被引量:18
标识
DOI:10.2174/1570161116666180101165306
摘要
Background: Hypertension (HT) is an important risk factor for cardiovascular disease and might precipitate pathology of the aortic valve. </P><P> Objective: To investigate the association of HT with aortic dysfunction (including both aortic regurgitation and stenosis) and the impact of antihypertensive treatment on the natural course of underlying aortic disease. </P><P> Methods: We performed a systematic review of the literature for all relevant articles assessing the correlation between HT and phenotype of aortic disease. </P><P> Results: Co-existence of HT with aortic stenosis and aortic regurgitation is highly prevalent in hypertensive patients and predicts a worse prognosis. Certain antihypertensive agents may improve haemodynamic parameters (aortic jet velocity, aortic regurgitation volume) and remodeling of the left ventricle, but there is no strong evidence of benefit regarding clinical outcomes. Renin-angiotensin system inhibitors, among other vasodilators, are well-tolerated in aortic stenosis. </P><P> Conclusion: Several lines of evidence support a detrimental association between HT and aortic valve disease. Therefore, HT should be promptly treated in aortic valvulopathy. Despite conventional wisdom, specific vasodilators can be used with caution in aortic stenosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI